Phase I/II trial of anti-CLDN18.2/PD-L1 recombinant humanized bispecific antibody Q-1802 plus XELOX in treatment-naive CLDN18.2-positive advanced GC/GEJ.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Peking University Cancer Hospital, Shandong First Medical University, Fujian Provincial Cancer Hospital, Third Affiliated Hospital of Harbin Medical University, Shanxi Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Shanxi Provincial Cancer Hospital, Zhejiang Provincial People's Hospital, First Affiliated Hospital of Xiamen University, Shanghai Medical College of Fudan University, Fudan University, Zhongshan Hospital, People's Hospital of Cangzhou, Xuzhou Cancer Hospital, Sir Run Run Shaw Hospital, Zhejiang University, Liaoning Cancer Hospital & Institute, Sixth Affiliated Hospital of Sun Yat-sen University, First Affiliated Hospital of Xinxiang Medical University, Henan Medical University, Henan University of Science and Technology, First Affiliated Hospital of Henan University of Science and Technology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162484641